专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080269237A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS 有权
标题翻译：包含作为HDAC抑制剂的哌嗪连接物的碳酸化合物
公开(公告)号：US20080269237A1
公开(公告)日：2008-10-30
申请号：US12165686
申请日：2008-07-01
申请人： Clare J. WATKINS , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
发明人： Clare J. WATKINS , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
IPC分类号： A61K31/506 , A61K31/495 , A61P35/00 , C12N9/99 , A61P25/28 , A61P25/16
CPC分类号： C07D213/74 , C07D239/42 , C07D295/185 , C07D295/192 , C07D295/26 , C07D317/58 , C07D333/60
摘要： This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
摘要翻译：本发明涉及抑制下式的HDAC（组蛋白脱乙酰酶）活性的某些氨基甲酸化合物：本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途抑制HDAC，以及治疗由HDAC，癌症，增殖性病症，牛皮癣等介导的病症。

2. 发明申请

US20110105572A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS 审中-公开
标题翻译：包含作为HDAC抑制剂的酰胺链接的碳酸化合物
公开(公告)号：US20110105572A1
公开(公告)日：2011-05-05
申请号：US12983971
申请日：2011-01-04
申请人： Clare J. Watkins , Maria Rosario Romero-Martin , Kathryn G. Moore , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M. Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E.S. Duffy
发明人： Clare J. Watkins , Maria Rosario Romero-Martin , Kathryn G. Moore , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M. Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E.S. Duffy
IPC分类号： A61K31/165 , C07C259/06 , C07C259/08 , A61K31/167 , C07D317/60 , A61K31/36 , C07D213/56 , A61K31/4409 , C07D307/54 , A61K31/341 , A61K31/166 , C07D271/08 , A61K31/4245 , C07D207/337 , A61K31/40 , A61K31/4406 , C07D209/20 , A61K31/405 , C07D333/24 , A61K31/381 , A61P35/00 , C12N5/02
CPC分类号： C07D207/337 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/277 , A61K31/38 , A61K31/381 , A61K31/426 , C07C233/49 , C07C233/83 , C07C235/34 , C07C237/36 , C07C255/57 , C07C259/06 , C07C259/08 , C07C2603/18 , C07D207/40 , C07D207/404 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/22 , C07D213/06 , C07D213/55 , C07D213/56 , C07D233/04 , C07D233/08 , C07D235/14 , C07D235/24 , C07D271/06 , C07D307/34 , C07D307/54 , C07D317/60 , C07D333/24 , C07D333/60 , C07D403/12 , Y02A50/411
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is a C5-20heteroaryl or C5-20carboaryl group and is optionally substituted; Q1 is a C2-7alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R1)C(═O)— or —C(═O)N(R1)—; R1 is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q2 is C1-7alkylene, C5-20arylene, C5-20arylene-C1-7alkylene, or C1-7alkylene-C5-20arylene having a backbone of at least 3 carbon atoms, and is optionally substituted; and pharmaceutically acceptable salts thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to treat proliferative conditions, such as cancer and psoriasis.
摘要翻译：本发明涉及一些抑制HDAC活性的活性氨基甲酸化合物，其具有下式：其中：A为C 5-20杂芳基或C 5-20碳氢芳基并且任选被取代; Q1是具有至少2个碳原子的主链的C2-7亚烷基，并且任选被取代; J是-N（R 1）C（= O） - 或-C（= O）N（R 1） - ; R 1是氢，C 1-7烷基，C 3-20杂环基或C 5-20芳基; 并且Q2是具有至少3个碳原子的主链的C 1-7亚烷基，C 5-20亚芳基，C 5-20亚芳基-C 1-7亚烷基或C 1-7亚烷基-C 5-20亚芳基，并且任选被取代; 及其药学上可接受的盐。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，并且例如治疗增殖性疾病如癌症和牛皮癣。

3. 发明授权

US07981895B2 Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors 有权
标题翻译：包含哌嗪键的氨基甲酸化合物作为HDAC抑制剂
公开(公告)号：US07981895B2
公开(公告)日：2011-07-19
申请号：US12165686
申请日：2008-07-01
申请人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
发明人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
IPC分类号： A61K31/497 , A61K31/4965
CPC分类号： C07D213/74 , C07D239/42 , C07D295/185 , C07D295/192 , C07D295/26 , C07D317/58 , C07D333/60
摘要： This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
摘要翻译：本发明涉及抑制下式的HDAC（组蛋白脱乙酰酶）活性的某些氨基甲酸化合物：本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途抑制HDAC，以及治疗由HDAC，癌症，增殖性病症，牛皮癣等介导的病症。

4. 发明申请

US20100249197A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS 失效
标题翻译：包含作为HDAC抑制剂的酰胺链接的碳酸化合物
公开(公告)号：US20100249197A1
公开(公告)日：2010-09-30
申请号：US12477493
申请日：2009-06-03
申请人： Clare J. Watkins , Maria Rosario Romero-Martin , Kathryn G. Moore , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E.S. Duffy
发明人： Clare J. Watkins , Maria Rosario Romero-Martin , Kathryn G. Moore , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E.S. Duffy
IPC分类号： A61K31/4406 , C07C259/06 , A61K31/165 , A61P35/00 , A61P17/06 , C07C259/08 , C07D317/54 , A61K31/36 , C07D213/56 , C07D307/54 , A61K31/341
CPC分类号： C07D207/337 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/277 , A61K31/38 , A61K31/381 , A61K31/426 , C07C233/49 , C07C233/83 , C07C235/34 , C07C237/36 , C07C255/57 , C07C259/06 , C07C259/08 , C07C2603/18 , C07D207/40 , C07D207/404 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/22 , C07D213/06 , C07D213/55 , C07D213/56 , C07D233/04 , C07D233/08 , C07D235/14 , C07D235/24 , C07D271/06 , C07D307/34 , C07D307/54 , C07D317/60 , C07D333/24 , C07D333/60 , C07D403/12 , Y02A50/411
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)— and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psorias
摘要翻译：本发明涉及抑制HDAC活性的一些活性氨基甲酸化合物，其具有式（1）其中：A为芳基; Q1是具有至少2个碳原子的骨架的芳基前导基团; J是选自：-NR 1 C（= O） - 和-C（= O）NR 1 - 的酰胺键; R1是酰氨基取代基; 而Q2是酸性引导组; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，并且例如抑制增殖性疾病如癌症和牛皮癣

5. 发明授权

US07569724B2 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors 失效
标题翻译：包含酰胺键作为HDAC抑制剂的氨基甲酸化合物
公开(公告)号：US07569724B2
公开(公告)日：2009-08-04
申请号：US10381791
申请日：2001-09-27
申请人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E. S. Duffy
发明人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E. S. Duffy
IPC分类号： C07C239/00
CPC分类号： C07D207/337 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/277 , A61K31/38 , A61K31/381 , A61K31/426 , C07C233/49 , C07C233/83 , C07C235/34 , C07C237/36 , C07C255/57 , C07C259/06 , C07C259/08 , C07C2603/18 , C07D207/40 , C07D207/404 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/22 , C07D213/06 , C07D213/55 , C07D213/56 , C07D233/04 , C07D233/08 , C07D235/14 , C07D235/24 , C07D271/06 , C07D307/34 , C07D307/54 , C07D317/60 , C07D333/24 , C07D333/60 , C07D403/12 , Y02A50/411
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)— and —C(═O)NR1-; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
摘要翻译：本发明涉及抑制HDAC活性的一些活性氨基甲酸化合物，其具有式（1）其中：A为芳基; Q1是具有至少2个碳原子的骨架的芳基前导基团; J是选自：-NR 1 C（-O） - 和-C（-O）NR 1 - 的酰胺键; R1是酰氨基取代基; 而Q2是酸性引导组; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药。本发明还涉及包含这种化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，并且例如抑制增殖性疾病如癌症和牛皮癣。

6. 发明申请

US20110275810A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS 审中-公开
标题翻译：包含作为HDAC抑制剂的哌嗪连接物的碳酸化合物
公开(公告)号：US20110275810A1
公开(公告)日：2011-11-10
申请号：US13184869
申请日：2011-07-18
申请人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
发明人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W. Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
IPC分类号： C07D295/26 , C07D405/10 , C07D403/04 , C07D401/04
CPC分类号： C07D213/74 , C07D239/42 , C07D295/185 , C07D295/192 , C07D295/26 , C07D317/58 , C07D333/60
摘要： This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
摘要翻译：本发明涉及抑制下式的HDAC（组蛋白脱乙酰酶）活性的某些氨基甲酸化合物：本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途抑制HDAC，以及治疗由HDAC，癌症，增殖性病症，牛皮癣等介导的病症。

7. 发明授权

US07880020B2 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors 失效
标题翻译：包含酰胺键作为HDAC抑制剂的氨基甲酸化合物
公开(公告)号：US07880020B2
公开(公告)日：2011-02-01
申请号：US12477493
申请日：2009-06-03
申请人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E S Duffy
发明人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Igor Starchenkov , Klara Dikovska , Rasma M Bokaldere , Vija Gailite , Maxim Vorona , Victor Andrianov , Daina Lolya , Valentina Semenikhina , Andris Amolins , C. John Harris , James E S Duffy
IPC分类号： C07D333/36 , C07D333/22 , C07D307/02
CPC分类号： C07D207/337 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/277 , A61K31/38 , A61K31/381 , A61K31/426 , C07C233/49 , C07C233/83 , C07C235/34 , C07C237/36 , C07C255/57 , C07C259/06 , C07C259/08 , C07C2603/18 , C07D207/40 , C07D207/404 , C07D209/14 , C07D209/16 , C07D209/18 , C07D209/22 , C07D213/06 , C07D213/55 , C07D213/56 , C07D233/04 , C07D233/08 , C07D235/14 , C07D235/24 , C07D271/06 , C07D307/34 , C07D307/54 , C07D317/60 , C07D333/24 , C07D333/60 , C07D403/12 , Y02A50/411
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)— and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psorias.
摘要翻译：本发明涉及抑制HDAC活性的一些活性氨基甲酸化合物，其具有式（1）其中：A为芳基; Q1是具有至少2个碳原子的骨架的芳基前导基团; J是选自：-NR 1 C（= O） - 和-C（= O）NR 1 - 的酰胺键; R1是酰氨基取代基; 而Q2是酸性引导组; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，并且例如抑制增殖性疾病如癌症和牛皮癣。

8. 发明授权

US07629343B2 Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors 失效
标题翻译：包含哌嗪键的氨基甲酸化合物作为HDAC抑制剂
公开(公告)号：US07629343B2
公开(公告)日：2009-12-08
申请号：US10509732
申请日：2003-04-03
申请人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
发明人： Clare J. Watkins , Maria-Rosario Romero-Martin , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Igor Starchenkov , Daina Lolya , Vija Gailite
IPC分类号： A61K31/497 , A61K31/4965 , C07D241/04 , C07D295/00 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00
CPC分类号： C07D213/74 , C07D239/42 , C07D295/185 , C07D295/192 , C07D295/26 , C07D317/58 , C07D333/60
摘要： This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or —C(═; O)—; J2 is independently —C(═O)— or —S(═O)2—; Q2 is independently an acid leader group; wherein: Cy is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is independently: a covalent bond; C1-7alkylene; or C1-7alkylene-X—C1-7alkylene, —X—C1-7alkylene, or C1-7alkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Q2 is independently: C4-8alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q2 is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or, C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
摘要翻译：本发明涉及抑制下式的HDAC（组蛋白脱乙酰酶）活性的某些氨基甲酸化合物：其中：Cy独立地为环基; Q1独立地是共价键或环状引导基团; 哌嗪-1,4-二基任选被取代; J1独立地是共价键或-C（ - ; O） - ; J2独立地是-C（-O） - 或-S（-O）2 - ; Q2独立为酸性引导基团; 其中：Cy独立地为：C 3-20碳环基，C 3-20杂环基或C 5-20芳基; 并且任选被取代; Q1独立地是共价键; C 1-7亚烷基; 或C 1-7亚烷基-X-C 1-7亚烷基，-X-C 1-7亚烷基或C 1-7亚烷基-X-，其中X是-O-或-S-; 并且任选被取代; Q2独立地为：C4-8亚烷基; 并且任选被取代; 并具有至少4个原子的骨架长度; 或：Q2独立地为：C 5-20亚芳基; C 5-20芳基-C 1-7亚烷基; C 1-7亚烷基-C 5 - 亚芳基; 或C 1-7亚烷基-C 5-20亚芳基-C 1-7亚烷基; 并且任选被取代; 并具有至少4个原子的骨架长度; 或其药学上可接受的盐，溶剂化物，酰胺，酯，醚，化学保护形式或前药。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，以及治疗由HDAC，癌症，增殖性病症，牛皮癣等介导的病症。

9. 发明授权

US07183298B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors 有权
公开(公告)号：US07183298B2
公开(公告)日：2007-02-27
申请号：US10953106
申请日：2004-09-30
申请人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Vija Gailite , Maxim Vorona , Irina Piskunova , Igor Starchenkov , Victor Andrianov , C. John Harris , James E. S. Duffy
发明人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Vija Gailite , Maxim Vorona , Irina Piskunova , Igor Starchenkov , Victor Andrianov , C. John Harris , James E. S. Duffy
IPC分类号： A01N43/40 , A61K31/44
CPC分类号： C07D213/40 , C07C311/06 , C07C311/13 , C07C311/16 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/29 , C07C2602/08 , C07D209/88 , C07D213/42 , C07D213/65 , C07D213/71 , C07D307/52 , C07D317/58
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

10. 发明授权

US06888027B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors 有权
标题翻译：包含磺酰胺键作为HDAC抑制剂的氨基甲酸化合物
公开(公告)号：US06888027B2
公开(公告)日：2005-05-03
申请号：US10381790
申请日：2001-09-27
申请人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Vija Gailite , Maxim Vorona , Irina Piskunova , Igor Starchenkov , Victor Andrianov , C. John Harris , James E. S. Duffy
发明人： Clare J Watkins , Maria Rosario Romero-Martin , Kathryn G Moore , James Ritchie , Paul W Finn , Ivars Kalvinsh , Einars Loza , Klara Dikovska , Vija Gailite , Maxim Vorona , Irina Piskunova , Igor Starchenkov , Victor Andrianov , C. John Harris , James E. S. Duffy
IPC分类号： A61K31/341 , A61K31/403 , A61K31/4406 , A61P17/06 , A61P35/00 , A61P43/00 , C07C311/06 , C07C311/08 , C07C311/10 , C07C311/13 , C07C311/16 , C07C311/17 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/29 , C07D209/82 , C07D209/88 , C07D213/40 , C07D213/42 , C07D213/65 , C07D213/71 , C07D307/52 , C07D317/58 , A01N37/28
CPC分类号： C07D213/40 , C07C311/06 , C07C311/13 , C07C311/16 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/29 , C07C2602/08 , C07D209/88 , C07D213/42 , C07D213/65 , C07D213/71 , C07D307/52 , C07D317/58
摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
摘要翻译：本发明涉及抑制HDAC活性的一些活性氨基甲酸化合物，其具有下式：（I）A为芳基; Q 1是共价键或芳基前导基团; J是选自以下的磺酰胺键：-S（-O）2 NR 1 - 和-NR 1 S（-O） > 2 - ; R1是亚磺酰氨基取代基; 而Q 2是酸性引导基团; 条件是如果J是-S（-O）2 NR 1 - ，则Q 1是芳基前导基团; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药。本发明还涉及包含这种化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制HDAC，并且例如抑制增殖性疾病如癌症和牛皮癣。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式